Pain Research Comes into Its Own

In the first case of its kind, a jury earlier this year found a physician guilty of undermedicating a patient for pain. Claiming that such an action amounted to elder abuse and recklessness, the judge awarded $1.5 million to the patient's family. The precedent-setting case occurred after the passage of a Congressional provision, the Decade of Pain Control and Research, which went into effect Jan. 1. Signed into law by then-President Bill Clinton and sponsored by the American Academy of Pain Medi

Written byJennifer Fisher Wilson
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

"Too many people with chronic pain are undertreated," says neuroscientist Allan I. Basbaum, department of anatomy chairman and member of the Keck Center for Integrative Neuroscience at the University of California, San Francisco. "Pain is difficult to measure. You can't see it and thus the medical community often underestimates the magnitude of a patient's pain. And because people die in pain, but not of pain, nobody wants to give money specifically to pain research."

Editor's Note: This is the fourth article in a series on the senses. The final installment, on the sense of smell, will be published in the December 10 issue.

Private foundation funds for pain research remain scant, but National Institutes of Health funding--partly in response to the congressional mandate--has become more abundant spending. According to NIH numbers, the 1995 FY budget for pain condition was $67.3 million, the 2002 FY budget is estimated at $157.1 million. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies